Literature DB >> 25492674

[Reliability and validity of the Japanese version of the Apathy Evaluation Scale].

Mari Kasai1, Kenichi Meguro, Kei Nakamura.   

Abstract

AIM: Clinicians need an objective scale to measure apathy in patients with dementia. However, different cutoff scores for the Apathy Evaluation Scale Informant version (AES-I), an international apathy scale, have been used in previous studies. The purpose of this study was to investigate the cutoff score, reliability and validity of the Japanese version of the AES-I (AES-I-J).
METHODS: We acquired the author's permission to translate the AES from English to Japanese. The subjects of this study included 50 patients with dementia living in institutions or the community. The mean (standard deviation; SD) age of the subjects was 82.7 (5.7) years, the mean (SD) educational level was 8.9 (2.7) years and the mean (SD) Mini-Mental State Examination score was 14.8 (8.1). We provided the caregivers with two apathy scales to assess each patient: the AES-I-J (re-test: four weeks later) and the Neuropsychiatric Inventory in Nursing Home version apathy score.
RESULTS: The mean (SD) score for the AES-I-J was 45.8 (16.2). For this test, Cronbach's α was 0.97, and the intraclass correlation coefficient of test-retest was 0.88 (95%CI: 0.72-0.95) (p<0.0001). In addition, the area under the receiver operating characteristic curve was 0.90 (95%CI: 0.78-1.00) (p<0.0001) and the cut-off score was 45/46, with a sensitivity of 89.5% and specificity of 81.0%.
CONCLUSIONS: Our findings suggest that the cutoff score for the AES-I-J is higher than that used in previous reports.

Entities:  

Mesh:

Year:  2014        PMID: 25492674     DOI: 10.3143/geriatrics.51.445

Source DB:  PubMed          Journal:  Nihon Ronen Igakkai Zasshi        ISSN: 0300-9173


  3 in total

1.  Apathy in Alzheimer's Disease Correlates with the Dopamine Transporter Level in the Caudate Nuclei.

Authors:  Niki Udo; Naoki Hashimoto; Takuya Toyonaga; Tomoyuki Isoyama; Yuka Oyanagi; Hisashi Narita; Tohru Shiga; Shin Nakagawa; Ichiro Kusumi
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2020-09-09

2.  Clinical utility and psychometric properties of the Apathy Evaluation Scale.

Authors:  Beatrice Lee; Carey Gleason; Emre Umucu
Journal:  Rehabil Psychol       Date:  2020-08

3.  Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations.

Authors:  Takayuki Kondo; Haruhiko Banno; Hidekazu Tomimoto; Haruhisa Inoue; Taro Okunomiya; Yoko Amino; Kayoko Endo; Akiyoshi Nakakura; Ryuji Uozumi; Akemi Kinoshita; Harue Tada; Satoshi Morita; Hidehiro Ishikawa; Akihiro Shindo; Ken Yasuda; Yosuke Taruno; Takakuni Maki; Takashi Suehiro; Kohji Mori; Manabu Ikeda; Koji Fujita; Yuishin Izumi; Kazutomi Kanemaru; Kenji Ishii; Kazue Shigenobu; Yumiko Kutoku; Yoshihide Sunada; Shinobu Kawakatsu; Shunji Shiota; Toshifumi Watanabe; Osamu Uchikawa; Ryosuke Takahashi
Journal:  BMJ Open       Date:  2021-06-30       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.